Senicapoc in Patients With Worsening Fibrotic Interstitial Lung Disease

This study is testing a drug called senicapoc in people whose lung scarring (fibrosis) is getting worse over time, a condition called progressive fibrotic interstitial lung disease (ILD) or idiopathic pulmonary fibrosis (IPF). Researchers want to see if this drug can slow the decline in lung function. **You may be eligible if...** - You are over 18 years old - You have been diagnosed with progressive fibrotic ILD or IPF - Your lung function (measured by a breathing test called FVC) is above 45% and has been declining by at least 5% per year over the past 6–24 months - You can walk at least 150 meters in a standard walk test - You have had a chest CT scan in the past 2 years - You are able to use contraception if you are of childbearing potential **You may NOT be eligible if...** - You have sickle cell disease - You are currently on immunosuppressive therapy - You have significant heart rhythm problems or liver problems - You have had cancer in the past 5 years - You have had a lung transplant or lung volume reduction surgery - You have severe pulmonary hypertension - You are currently taking certain medications like warfarin, methotrexate, or high-dose prednisone Talk to your doctor to see if this trial is right for you.